AIKON Health, a digital health spin-off from TNO, has successfully raised €1.2 million in seed funding to advance its wearable technology for remote monitoring of

AIKON Health是TNO的数字健康分支公司，已成功筹集了120万欧元的种子资金，以推进其用于远程监测的可穿戴技术。

heart failure

心力衰竭

. The investment will accelerate product development and early clinical validation.

投资将加速产品开发和早期临床验证。

investments

投资

come from TTT Medtech fund, the Brabant Development Agency (BOM), Brabant Startup Fonds (BSF), Rabo Innovation Loan (RIL), and TNO Ventures.

来自TTT医疗技术基金、布拉班特发展局（BOM）、布拉班特创业基金（BSF）、拉博创新贷款（RIL）和TNO风险投资。

In Europe, more than 15 million people live with heart failure. Without timely interventions, lifestyle changes, and adherence to medication, heart failure often progresses and can lead to repeated hospitalizations or even death. AIKON Health is developing a wearable device that allows cardiologists and cardiac nurses to better monitor their patients.

在欧洲，超过1500万人患有心力衰竭。如果不及时干预、改变生活方式并坚持服药，心力衰竭往往会恶化，可能导致反复住院甚至死亡。AIKON Health正在开发一种可穿戴设备，帮助心脏病学家和心脏科护士更好地监测患者。

This helps heart failure patients manage their condition at home. AIKON Health aims to reduce the number of hospital readmissions for heart failure patients by at least 25%..

这有助于心力衰竭患者在家中管理自己的病情。AIKON Health 的目标是将心力衰竭患者的再次住院率至少降低 25%。

Thiru Kanagasabapathi – Founder and CEO AIKON Health: ‘We’re grateful to have the backing of such a committed and focused group of investors. This underscores the potential of medical technology emerging from the Brainport region and the strength of our innovation ecosystem. Their support accelerates our path towards FDA approval, an ambitious milestone we’re pursuing just a few years after founding.’.

Thiru Kanagasabapathi – AIKON Health创始人兼首席执行官：“我们非常感激拥有这样一群坚定且专注的投资者的支持。这凸显了来自Brainport地区的医疗技术的潜力以及我们创新生态系统的实力。他们的支持加快了我们迈向FDA批准的进程，这是我们创立公司仅几年后就在追求的一个雄心勃勃的里程碑。”

The funding round is led by the Thematic Tech Transfer (TTT) Medtech program with active involvement from BOM, BSF, RIL and TNO Ventures. Harm de Vries, Director of TTT Medtech: ‘AIKON Health exemplifies how cutting-edge research at TNO can lead to impactful medtech solutions. Their wearable for heart failure monitoring is exactly the kind of clinically relevant innovation TTT Medtech is proud to support - turning science into better care at home.’.

本轮融资由主题技术转移（TTT）医疗科技项目主导，BOM、BSF、RIL和TNO Ventures积极参与。TTT医疗科技总监Harm de Vries表示：“AIKON Health充分展示了TNO的前沿研究如何能够带来具有影响力的医疗科技解决方案。他们用于心力衰竭监测的可穿戴设备正是TTT医疗科技引以为豪支持的那种临床相关创新——将科学转化为更好的家庭护理。”

Albertien Greijdanus, Senior Investment Manager BOM: ‘As BOM, we are excited to invest in AIKON Health, whose wearable technology directly addresses the critical need for continuous monitoring of heart failure patients as they transition from hospital to home. Their solution enables earlier intervention, reduces readmissions, and supports better, patient-centered care beyond the hospital setting.’.

阿尔伯蒂恩·格雷伊丹努斯，BOM高级投资经理：“作为BOM，我们很高兴投资AIKON Health，其可穿戴技术直接满足了心力衰竭患者从医院过渡到家庭过程中对持续监测的关键需求。他们的解决方案能够实现更早的干预，减少再入院率，并在医院以外支持更好、以患者为中心的护理。”

Shifting care from hospital to home

将护理从医院转移到家庭

Each year, the Netherlands records 30,000 new hospital admissions for heart failure, adding over €800 million in avoidable healthcare costs and placing significant strain on already stretched resources. After discharge, patients often need frequent outpatient visits for monitoring and medication adjustments.

每年，荷兰有 30,000 例新发心力衰竭住院病例，增加了超过 8 亿欧元的可避免医疗费用，并对本已紧张的资源造成重大压力。出院后，患者通常需要频繁的门诊随访进行监测和药物调整。

This increases pressure on clinics and adds stress for patients. AIKON Health is transforming heart failure management with a modular wearable solution that combines a discreet chest sensor and an arm sensor, enabling continuous monitoring of key indicators from the comfort of home. It allows clinicians to make timely and informed decisions remotely, helping reduce hospital visits, improve quality of life for patients, and ease the load on the healthcare system..

这增加了诊所的压力，也给患者增添了压力。AIKON Health 正在通过一种模块化的可穿戴解决方案彻底改变心力衰竭管理，该解决方案结合了隐蔽的胸部传感器和手臂传感器，让用户在家就能舒适地持续监测关键指标。它使临床医生能够远程及时做出明智的决策，帮助减少医院就诊次数，提高患者的生活质量，并减轻医疗系统的负担。

Boosting innovative technologies

推动创新技术的发展

TNO Ventures was established to drive the growth of breakthrough technologies by accelerating the journey from lab to market. Through spin-offs like AIKON Health, TNO aims to strengthen the Dutch innovation ecosystem and support the scaling of high-potential startups into global players.

TNO Ventures 成立的目的是通过加速实验室到市场的进程，推动突破性技术的增长。通过像 AIKON Health 这样的分拆公司，TNO 旨在加强荷兰的创新生态系统，并支持高潜力初创企业成长为全球参与者。

https://www.bionity.com/en/news/1186573/tno-spin-off-aikon-health-secures-1-2-million-seed-round-to-advance-remote-heart-failure-monitoring.html

https://www.bionity.com/zh/news/1186573/tno子公司Aikon Health获得120万欧元种子轮融资，推动远程心力衰竭监测技术发展.html

Living heart muscle slices drive RNA research into heart failure

活体心脏肌肉切片推动心力衰竭的RNA研究

Researchers place living human heart tissue in a nutrient solution and use it to test new drugs and innovative approaches to combat heart failure

研究人员将活的人类心脏组织放入营养液中，用来测试新药和对抗心力衰竭的创新方法。

Read news

读新闻

Most read news

最热门的新闻

1

1

Newly identified group of nerve cells in the brain regulates bodyweight

新发现的大脑神经细胞群调节体重

2

2

Hold the cream and sugar: black coffee linked to lower risk of death

不加奶油和糖：黑咖啡与较低的死亡风险相关

3

3

Tumor profiling: 43,000 data points against melanoma

肿瘤分析：43,000个数据点对抗黑色素瘤

4

4

Yeast Produces Human DNase1 for the First Time

酵母首次产生人类DNase1

5

5

Possible anti-aging compounds found in blood bacteria

血液细菌中发现可能的抗衰老化合物

Topics

主题

seed financing

种子融资

wearables

可穿戴设备

heart failures

心力衰竭

investments

投资

medical technology

医学技术

heart failure

心力衰竭

Show all

显示全部

Show less

显示较少

Organizations

组织机构

TNO

荷兰应用科学研究组织（TNO）